Feedback
CV2.1 Screen by IFA with Reflex to Titer
2013956
Ordering Recommendation

Consider ordering for individuals with paraneoplastic encephalomyelitis, chorea, cerebellar degeneration, optic neuritis, and peripheral neuropathy. May aid in diagnosis of occult or recurrent tumor.

Mnemonic
CV2.1 SCRN
Methodology
Semi-Quantitative Indirect Fluorescent Antibody
Performed
Thu
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Serum Separator Tube (SST) or Plain Red 
Specimen Preparation
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL) 
Storage/Transport Temperature
Refrigerated 
Unacceptable Conditions
Hemolyzed, contaminated, or severely lipemic specimens 
Remarks
 
Stability
Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year 
Reference Interval
Less than 1:10
Interpretive Data
CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
If CV2.1 Antibody IgG Screen by IFA is positive, then CV2.1 Antibody IgG Titer by IFA will be added. Additional charges apply.
CPT Code(s)
Components
Component Test Code*Component Chart NameLOINC
2013959CV2.1 Antibody IgG Screen by IFA
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases